{"schema_version":"secwatch.filing_event.v1","accession":"0001453687-25-000119","form_type":"8-K","ticker":"RNAC","cik":"0001453687","company_name":"Cartesian Therapeutics, Inc.","filed_at":"2025-11-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.444479+00:00","generated_at":"2026-05-16T23:35:47.076009+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"confidence":"high","headline":"Cartesian Q3 net loss $35.9M; cash $145.1M; AURORA trial on track","bullets":["Net loss of $35.9M ($1.38/share) vs $24.2M ($1.13/share) in Q3 2024.","Cash, equivalents and restricted cash $145.1M, expected to fund ops into mid-2027.","Phase 3 AURORA enrollment on track; ~100 participants, primary endpoint at Month 4.","Preliminary Phase 2 SLE data and pediatric basket trial initiation expected by end of 2025.","R&D expense $13.8M (+21% YoY) due to AURORA trial and headcount growth."],"urls":{"canonical":"https://secwatch.observer/filing/0001453687-25-000119","json":"https://secwatch.observer/filing/0001453687-25-000119.json","markdown":"https://secwatch.observer/filing/0001453687-25-000119.md","text":"https://secwatch.observer/filing/0001453687-25-000119.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1453687/000145368725000119/0001453687-25-000119-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1453687/000145368725000119/rnac-20251106.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T23:35:47.076009+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}